Access Biotechnology

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
The average size of a deal this fund participated in
Portfolio companies 9
Rounds per year 0.31
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Access Biotechnology:
Typical Co-investors
Access Biotechnology is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Access Biotechnology:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Ascot Capital Partners England, London, United Kingdom
Chengdu Hometown City Investment Chengdu, China, Sichuan
China Minsheng Bank Beijing, Beijing, China
Dongfeng Motor Group China, Hubei, Wuhan
Emami India, Kolkata, West Bengal
Huaxinke Intelligent Manufacturing Technology China, Guangdong, Guangzhou
Inovio Pharmaceuticals Pennsylvania, Plymouth Meeting, United States
M3 Investimentos -
McClatchy Interactive North Carolina, Raleigh, United States
Mutschler Ventures AG Baar, Switzerland, Zug
Navitas Ventures Australia, New South Wales, Sydney
Pretiosum Ventures England, London, United Kingdom
Prosper Capital -
Sensegain Asset Management Beijing, Beijing, China
Shangyan Jingji Zixun -
Syddansk Venture Denmark, Kolding, Syddanmark
Tongmeng Touzi Beijing, China, Haidian
Xinjiang Xinxi Guquan Touzi China, Ürümqi, Xinjiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Curie Therapeutics

Health Care
$75M01 Dec 2021 Boston, Massachusetts, United States

Recludix Pharma

$60M15 Nov 2021 San Diego, California, United States

Disc Medicine

Health Care
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Nimbus Therapeutics

Alternative Medicine
Health Care
$105M13 Jul 2021 Cambridge, Massachusetts, United States

Eliem Therapeutics

Health Care
$60M24 May 2021 Washington, United States

Eliem Therapeutics

Health Care
$80M25 Mar 2021 Washington, United States

DTx Pharma

$100M01 Mar 2021 San Diego, California, United States

Day One Biopharmaceuticals

Health Care
$130M10 Feb 2021 South San Francisco, California, United States

Verona Pharma

$200M17 Jul 2020 London, England, United Kingdom
Disc Medicine Raises $90M in Series B Funding

– Disc Medicine from Cambridge MA develops therapeutic candidates for hematology.
– Series B $90M round was led by OrbiMed and attracted new investor – Arix Bioscience as well as existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
– The new investment will be aimed at developing the company’s hematology pipeline of therapeutic candidates.

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

– Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
– The round was led by BVF Partners L.P., with participation from existing investors including RA Capital Management and Atlas Venture.
Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
– In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Access Biotechnology?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: